8-Gingerol
Based on 5 publication(s) in Google Scholar
8-Gingerol can be found in the rhizome of ginger (Z. officinale) and has oral bioactivity. It activates TRPV1, with an EC50 value of 5.0 µM. 8-Gingerol inhibits COX-2 and also suppresses the growth of H. pylori in vitro. Additionally, 8-Gingerol exhibits anticancer, antioxidant, and anti-inflammatory properties by inhibiting the epidermal growth factor receptor (EGFR) and modulating its downstream STAT3/ERK pathway to suppress the proliferation, migration, and invasion of colorectal cancer cells. 8-Gingerol also exerts immunosuppressive effects by inhibiting oxidative stress, inducing cell cycle arrest, promoting apoptosis, and regulating autophagy. Furthermore, 8-Gingerol has cardioprotective effects. 8-Gingerol is promising for research in the fields of cancer, infection, immunosuppression, and cardiovascular diseases.
For research use only. We do not sell to patients.
- Purity: 99.82%
- CAS No.: 23513-08-8
- Formula: C19H30O4
- Molecular Weight:322.44
-
Storage:
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications Citing Use of MedChemExpress (MCE) 8-Gingerol
MoreAll EGFR Isoforms
MoreAll Caspase Isoforms
More
Biological Activity
|
MMP-9 |
Caspase-9 |
8-Gingerol (0-70 µM, 24-72 hours) can inhibit the proliferation of HCT116 and DLD1 colorectal cancer cells, induce G0/G1 phase cell cycle arrest, and significantly promote apoptosis in HCT116 cells[3]. 8-Gingerol (0-70 µM, 48 hours) significantly inhibits the migration and invasion abilities of the cells, and its effect is dependent on the EGFR/STAT3/ERK pathway[3]. 8-Gingerol (100 µM, 48 hours) can reduce the effective concentration of 5-FU in HCT116 and DLD1 colorectal cancer cells, and in combination treatment, it may help reduce the toxicity of 5-FU[3]. 8-Gingerol (40, 80 µg/mL, 24 hours) significantly inhibits the LPS (HY-D1056) and Concanavalin A (HY-P2149) induced splenocyte proliferation, exhibiting immunosuppressive effects[4]. 8-Gingerol (10, 20 µM, 48 hours) inhibits autophagy and apoptosis in myocardial fibrosis by regulating the PI3K/Akt/mTOR signaling pathway, showing significant cardioprotective effects[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCT116 (colorectal cancer), DLD1 (colorectal cancer)
-
Concentration:0, 10, 30, 50, 70 µM
-
Incubation Time:24h, 48h, 72h
-
Result:Dose-dependently inhibited HCT116 and DLD1 cell proliferation, with IC50 values of HCT116: 77.4 µM (48h), DLD1: 53.7 µM (48h)
-
Cell Line:HCT116 (colorectal cancer), DLD1 (colorectal cancer)
-
Concentration:0, 10, 30, 50, 70 µM
-
Incubation Time:48h
-
Result:Significantly induced G0/G1 cell cycle arrest in HCT116 and DLD1 cells.
-
Cell Line:HCT116 (colorectal cancer), DLD1 (colorectal cancer)
-
Concentration:0, 10, 30, 50, 70 µM
-
Incubation Time:48h
-
Result:Dose-dependently increased the apoptosis rate in HCT116 cells, but no significant change in DLD1 cells.
-
Cell Line:Cardiac cells from ISO-induced myocardial fibrosis mouse model
-
Concentration:10, 20 µM
-
Incubation Time:48h
-
Result:Significantly down-regulated the activity of MMP-9, Caspase-9, and Bax proteins, significantly up-regulated the activity of Bcl-2 protein, and inhibited apoptosis.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:OVA-immunized mice (BALB/c male mice, 5 weeks old, 18-22g, immunized with ovalbumin (OVA))[4]
-
Dosage:25, 50, 100 mg/kg
-
Administration:Intraperitoneal injection (i.p.), once daily for 7 consecutive days
-
Result:Significantly suppressed LPS-, ConA-, and OVA-induced splenocyte proliferation in OVA-immunized mice and significantly reduced the percentage of CD19+ B cells and CD3+ T cells at high doses (50, 100 mg/kg)
-
Animal Model:Isoproterenol (ISO)-induced myocardial fibrosis (MF) mouse model, Kunming mice (male, 6-8 weeks old, 15-20g)[5]
-
Dosage:10 mg/kg (low dose), 20 mg/kg (high dose)
-
Administration:Intraperitoneal injection (i.p.), once daily for 14 days
-
Result:Significantly reduced the heart weight, left ventricle weight index, CK, LDH levels, ROS generation, and pathological heart damage induced by ISO.
Chemical Information
-
CAS No. 23513-08-8
-
Appearance <29°C Solid,>30°C Liquid
-
Molecular Weight 322.44
-
Formula C19H30O4
-
Color White to yellow
-
SMILES
CCCCCCC[C@H](O)CC(CCC1=CC=C(O)C(OC)=C1)=O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Bioact Mater
Lipidomic analysis of plant-derived extracellular vesicles for guidance of potential anti-cancer therapy. [Abstract]2024 Dec 10:46:82-96. PMID: 39737211 -
Food Chem
2024 Sep 15:452:139425. PMID: 38744128 -
Phytomedicine
Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]2025 May:140:156484. PMID: 40090046 -
Arch Pharm Res
Cartilage extracellular matrix regeneration with 10-gingerol via KEAP1-NRF2-ARE axis for osteoarthritis therapy. [Abstract]2025 Dec;48(11-12):1460-1481. PMID: 41212495 -
ChemMedChem
Machine Learning-Driven Discovery of Structurally Related Natural Products as Activators of the Cardiac Calcium Pump SERCA2a. [Abstract]2025 Jan 23:e202400913. PMID: 39853697
Solvent & Solubility
DMSO : ≥ 100 mg/mL (310.14 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.75 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.75 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Dedov, V.N., et al. Gingerols: a novel class of vanilloid receptor (VR1) agonists. Br. J. Pharmacol. 137(6), 793-798 (2002). [Content Brief]
[2]. Chrubasik, S., et al. Zingiberis rhizoma: A comprehensive review on the ginger effect and efficacy profiles. Phytomedicine 12(9), 684-701 (2005). [Content Brief]
[3]. Hu SM, et al. 8‑Gingerol regulates colorectal cancer cell proliferation and migration through the EGFR/STAT/ERK pathway. Int J Oncol. 2020 Jan;56(1):390-397. [Content Brief]
[4]. Lu J, et al. Immunosuppressive activity of 8-gingerol on immune responses in mice. Molecules. 2011 Mar 22;16(3):2636-45. [Content Brief]
[5]. Xue Y, et al. 8-Gingerol Ameliorates Myocardial Fibrosis by Attenuating Reactive Oxygen Species, Apoptosis, and Autophagy via the PI3K/Akt/mTOR Signaling Pathway. Front Pharmacol. 2021 Jul 28;12:711701. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1014 mL | 15.5068 mL | 31.0135 mL | 77.5338 mL |
| 5 mM | 0.6203 mL | 3.1014 mL | 6.2027 mL | 15.5068 mL | |
| 10 mM | 0.3101 mL | 1.5507 mL | 3.1014 mL | 7.7534 mL | |
| 15 mM | 0.2068 mL | 1.0338 mL | 2.0676 mL | 5.1689 mL | |
| 20 mM | 0.1551 mL | 0.7753 mL | 1.5507 mL | 3.8767 mL | |
| 25 mM | 0.1241 mL | 0.6203 mL | 1.2405 mL | 3.1014 mL | |
| 30 mM | 0.1034 mL | 0.5169 mL | 1.0338 mL | 2.5845 mL | |
| 40 mM | 0.0775 mL | 0.3877 mL | 0.7753 mL | 1.9383 mL | |
| 50 mM | 0.0620 mL | 0.3101 mL | 0.6203 mL | 1.5507 mL | |
| 60 mM | 0.0517 mL | 0.2584 mL | 0.5169 mL | 1.2922 mL | |
| 80 mM | 0.0388 mL | 0.1938 mL | 0.3877 mL | 0.9692 mL | |
| 100 mM | 0.0310 mL | 0.1551 mL | 0.3101 mL | 0.7753 mL |